levofloxacin has been researched along with cefdinir in 18 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (cefdinir) | Trials (cefdinir) | Recent Studies (post-2010) (cefdinir) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 33 | 0 | 10 |
| 4,346 | 581 | 2,209 | 272 | 50 | 68 |
| Protein | Taxonomy | levofloxacin (IC50) | cefdinir (IC50) |
|---|---|---|---|
| SUMO-1 | Homo sapiens (human) | 6.25 | |
| low molecular weight phosphotyrosine protein phosphatase isoform c | Homo sapiens (human) | 19.6 | |
| carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 isoform 1 | Homo sapiens (human) | 4.48 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 12 (66.67) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Appelbaum, PC; Credito, KL; DeWasse, B; Kosowska-Shick, K; McGhee, P; Pankuch, GA | 1 |
| Brown, SD; Critchley, IA; Janjic, N; Tillotson, GS; Traczewski, MM | 1 |
| Brown, SD; Critchley, IA; Jacobs, MR; Janjic, N; Tillotson, GS; Traczewski, MM | 1 |
| Appelbaum, PC; Ednie, LM; Kosowska-Shick, K; McGhee, P | 1 |
| Iwata, S; Murayama, SY; Nakayama, E; Sakata, H; Seki, C; Sunakawa, K; Sunaoshi, K; Ubukata, K | 1 |
| Distèche-Nguyen, M; Gerards, T; Luxen, A; Miguet, L; Pasha, FA; Thomas, A; Zervosen, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hikida, M; Igarashi, A; Itahashi, K; Kitamura, M; Shiba, T | 1 |
| Hirai, K; Hiramatsu, K; Kishi, K; Murakami, J; Nasu, M; Yamasaki, T | 1 |
| Ishii, Y; Miyazaki, S; Okamoto, H; Tateda, K; Yamaguchi, K | 1 |
| Hashido, H; Ishigo, S; Iwata, I; Matsubara, S; Matsukawa, Y; Mikamo, H; Sawamura, H; Suematsu, H; Tamaya, T | 1 |
| Hasegawa, M; Kobayashi, I; Matsuzaki, K; Sato, Y; Shikano, M; Watabe, E; Yoshimori, K | 1 |
| Hasegawa, M; Kobayashi, I; Matsuzaki, K; Sato, Y; Shikano, M; Watabe, E; Yamanaka, N; Yoshimori, K | 1 |
| Busman, TA; Henry, DC; Kapral, D; Paris, MM | 1 |
| Fujisawa, M; Kitagawa, K; Nomi, M; Shigemura, K; Takami, N; Yamada, N | 1 |
| Crawford, SB; Davis, WH; Geno, KA; Magee, MR; Monks, SM | 1 |
1 review(s) available for levofloxacin and cefdinir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for levofloxacin and cefdinir
| Article | Year |
|---|---|
Cefdinir versus levofloxacin in patients with acute rhinosinusitis of presumed bacterial etiology: a multicenter, randomized, double-blind study.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Cefdinir; Cephalosporins; Double-Blind Method; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Severity of Illness Index; Sinusitis; Treatment Outcome | 2004 |
16 other study(ies) available for levofloxacin and cefdinir
| Article | Year |
|---|---|
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
Topics: Amidohydrolases; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Peptides; Pneumococcal Infections; Species Specificity; Streptococcus pneumoniae; Time Factors | 2007 |
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Infections; beta-Lactams; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Geography; Haemophilus influenzae; Health Surveys; Humans; Moraxella catarrhalis; Penicillin Resistance; Respiratory Tract Infections; Streptococcus pneumoniae; Trimethoprim, Sulfamethoxazole Drug Combination; United States | 2007 |
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactams; Child; Child, Preschool; Drug Resistance, Bacterial; Humans; Infant; Microbial Sensitivity Tests; Phenotype; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; United States | 2008 |
Comparative antipneumococcal activities of sulopenem and other drugs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Lactams; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Streptococcus pneumoniae | 2009 |
Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections.
Topics: Adolescent; Adult; Aged; Bacterial Capsules; Child; Child, Preschool; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Infant; Infant, Newborn; Levofloxacin; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Polymerase Chain Reaction; Streptococcus agalactiae | 2009 |
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
Topics: Computational Biology; Computer Simulation; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Ligands; Penicillin-Binding Proteins; Protein Binding; Streptococcus pneumoniae; Structure-Activity Relationship | 2009 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Carrier Proteins; Cefdinir; Cephalosporins; Dipeptidases; Drug Stability; Escherichia coli Proteins; Hexosyltransferases; Imipenem; Lactams; Levofloxacin; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Ofloxacin; Penicillin-Binding Proteins; Peptidoglycan Glycosyltransferase; Peptidyl Transferases; Protein Binding; Serine-Type D-Ala-D-Ala Carboxypeptidase; Thienamycins | 1999 |
Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro.
Topics: Animals; Anti-Bacterial Agents; Bacterial Toxins; Cefdinir; Cephalosporins; Chlorocebus aethiops; Clindamycin; Dose-Response Relationship, Drug; Escherichia coli O157; Fosfomycin; Humans; Latex Fixation Tests; Levofloxacin; Microbial Sensitivity Tests; Miocamycin; Ofloxacin; Roxithromycin; Shiga Toxin 1; Shiga Toxin 2; Time Factors; Vero Cells | 2000 |
Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against gram-positive clinical isolates in Japan.
Topics: Amoxicillin; Anti-Bacterial Agents; Cefdinir; Cephalosporins; Community-Acquired Infections; Drug Resistance, Microbial; Erythromycin; Gram-Positive Bacteria; Humans; Japan; Ketolides; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Ofloxacin; Penicillins; Respiratory Tract Infections; Staphylococcus aureus | 2000 |
[The frequency of Streptococcus pneumoniae strains and sensitivity surveillance for several antibiotics in Gifu Prefecture].
Topics: Amoxicillin; Anti-Bacterial Agents; Cefaclor; Cefdinir; Cefixime; Cefmenoxime; Cefpodoxime; Ceftizoxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Clindamycin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; Japan; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Minocycline; Naphthyridines; Ofloxacin; Penicillin G; Penicillins; Streptococcus pneumoniae; Thienamycins | 2000 |
[Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Cefdinir; Cephalosporins; Ciprofloxacin; Dosage Forms; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Macrolides; Ofloxacin; Otorhinolaryngologic Diseases; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae; Time Factors; Urinary Tract Infections | 2002 |
[Susceptibility of major pathogens of acute pharyngitis and tonsillitis to levofloxacin and other oral antimicrobial drugs].
Topics: Acute Disease; Ampicillin; Anti-Infective Agents; Azithromycin; Cefdinir; Cefpodoxime; Ceftizoxime; Cephalosporins; Clarithromycin; Enterobacteriaceae; Haemophilus influenzae; Humans; Levofloxacin; Ofloxacin; Penicillin G; Pharyngitis; Streptococcus pneumoniae; Streptococcus pyogenes; Tonsillitis | 2003 |
Use of oral third generation cephalosporins and quinolones and occurrence of antibiotic-resistant strains in the neurogenic bladder (NB) outpatient setting: a retrospective chart audit.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimicrobial Stewardship; Cefdinir; Cephalosporins; Drug Prescriptions; Drug Resistance, Bacterial; Female; Hospitals, Rehabilitation; Humans; Japan; Levofloxacin; Male; Middle Aged; Outpatients; Quinolones; Retrospective Studies; Spinal Cord Injuries; Urinary Bladder, Neurogenic; Young Adult | 2020 |
Assessment of nationally recommended antibiotics for treatment of UTI in U.S.-Mexico border emergency departments.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Cefdinir; Cefuroxime; Cephalexin; Ciprofloxacin; Emergency Service, Hospital; Fluoroquinolones; Humans; Levofloxacin; Mexico; Nitrofurantoin; Retrospective Studies; Tetracyclines; Trimethoprim, Sulfamethoxazole Drug Combination; United States; Urinary Tract Infections | 2022 |